To explore response rates using pooled data from two fixed-dose trials of brexpiprazole in patients with agitation associated with dementia due to Alzheimer's disease (AD).
No takes yet. Share an insight, caveat, or question.
Behl et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: